1511 related articles for article (PubMed ID: 28270207)
1. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
Fan Q; Ming WK; Yip WY; You JHS
Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
Diel R; Hittel N; Schaberg T
Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
Wolfson LJ; Walker A; Hettle R; Lu X; Kambili C; Murungi A; Knerer G
PLoS One; 2015; 10(3):e0120763. PubMed ID: 25794045
[TBL] [Abstract][Full Text] [Related]
5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
6. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
[TBL] [Abstract][Full Text] [Related]
7. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
Gotham D; Fortunak J; Pozniak A; Khoo S; Cooke G; Nytko FE; Hill A
J Antimicrob Chemother; 2017 Apr; 72(4):1243-1252. PubMed ID: 28073970
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
Park HY; Ku HM; Sohn HS; Seo HS; Yung Lee H; Hwa Lim K; Kwon JW
Clin Ther; 2016 Mar; 38(3):655-67.e1-2. PubMed ID: 26907504
[TBL] [Abstract][Full Text] [Related]
9. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
10. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
11. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Wolfson LJ; Gibbert J; Wirth D; Diel R
Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
[No Abstract] [Full Text] [Related]
13. Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
Byun JH; Park JA; Kang HR; Shin JY; Lee EK
Clin Drug Investig; 2016 Nov; 36(11):957-968. PubMed ID: 27465204
[TBL] [Abstract][Full Text] [Related]
14. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
[TBL] [Abstract][Full Text] [Related]
15. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
17. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
19. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
20. Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment.
Zwerling A; Dowdy D; von Delft A; Taylor H; Merritt MW
Int J Tuberc Lung Dis; 2017 Nov; 21(11):69-74. PubMed ID: 29025487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
